Claim · 2023-07-12 · announcement · Stated in source · Supported

Recursion announced on 12 July 2023 plans to develop AI foundation models for biology and chemistry which, in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using NVIDIA cloud services, with possible release on NVIDIA's BioNeMo.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Recursion Pharmaceuticals → announced a partnership with → NVIDIA

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Recursion Pharmaceuticalsannounced a partnership with ↓NVIDIA

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2023-07-12 · announcement Records dated 2023 →
Activity stage: announced

Scope and limitsAn announced collaboration and stated intentions ("plans", "intends", "possible"); the record does not establish that any model was trained, licensed or released.

The evidence 02

primary sourceSupports the claim

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K) · 2023-07-12

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using NVIDIA cloud services.”

Location in source first paragraph

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 7e670958d0987c0c50a7432a89091bdc6ca094d02da274eb6bc8774111b9bab7). Exhibit 99.1 to Form 8-K filed 2023-07-12, accession 0001601830-23-000050, as served by SEC EDGAR on 2026-10-30. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K), “Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery”, 2023-07-12.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (34 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

primary sourceSupports the claim

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K) · 2023-07-12

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“for possible commercial license/release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery.”

Location in source third paragraph

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 7e670958d0987c0c50a7432a89091bdc6ca094d02da274eb6bc8774111b9bab7). Exhibit 99.1 to Form 8-K filed 2023-07-12, accession 0001601830-23-000050, as served by SEC EDGAR on 2026-10-30. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K), “Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery”, 2023-07-12.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (15 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An organisation announced a collaboration or partnership with a named counterparty, as the announcement states it (stage announced). It is not evidence that the work was performed, that a payment was made or that the arrangement continues; an “up to” amount stays in the statement.

Date. Date of Recursion's press release.

Record ID aib-co-recursion-nvidia-collaboration-2023